4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021

These new findings indicate the potential to predict patients most likely to respond to MRx0518 therapy based on tumor biology.